Premium
BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta‐analysis
Author(s) -
Clancy C.,
Burke J. P.,
Kalady M. F.,
Coffey J. C.
Publication year - 2013
Publication title -
colorectal disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.029
H-Index - 89
eISSN - 1463-1318
pISSN - 1462-8910
DOI - 10.1111/codi.12427
Subject(s) - medicine , colorectal cancer , oncogene , mutation , oncology , cancer , phenotype , cancer research , gene , genetics , biology , cell cycle
Aim Colorectal cancer is a heterogeneous disease with multiple underlying genetic mutations resulting in different phenotypes. Mutation in the v‐ R af murine sarcoma viral oncogene homolog B 1 ( BRAF ) proto‐oncogene is an important event in the methylator pathway. There is no consensus, however, on the clinicopathological characteristics associated with BRAF mutation. Method A comprehensive search for published studies examining the effect of BRAF mutation on colorectal cancer was performed. Random effects methods were used to combine data. Results Data were retrieved from 21 studies describing 9885 patients. BRAF associated colorectal cancer is associated with proximal tumour location ( OR 5.222, 95% CI 3.801–7.174, P < 0.001), T 4 tumours ( OR 1.761, 95% CI 1.164–2.663, P = 0.007) and poor differentiation ( OR 3.816, 95% CI 2.714–5.365, P < 0.001) and is negatively associated with male sex ( OR 0.623, 95% CI 0.505–0.769, P < 0.001), age of diagnosis under 60 years ( OR 0.453, 95% CI 0.280–0.733, P = 0.001) and rectal cancer ( OR 0.266, 95% CI 0.122–0.422, P < 0.001). Conclusion BRAF mutation appears to be associated with distinct, unfavourable clinicopathological characteristics in colorectal cancer.